VanEck Video Gaming and eSports ETF vs Vaxcyte Inc. Common Stock — how do they compare? VanEck Video Gaming and eSports ETF trades at $99.09 (market cap $256.17M), while Vaxcyte Inc. Common Stock trades at $67.27 (market cap $10.63B). The key difference: Vaxcyte Inc. Common Stock is far larger — about 41.5× VanEck Video Gaming and eSports ETF's market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, VanEck Video Gaming and eSports ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Video Gaming and eSports ETF for 68 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| ESPO | PCVX | |
|---|---|---|
Market Cap | $256.17M | $10.63B |
Volume | 15,265 | 1,525,205 |
Sector | Sector/Thematic | Health |
52-Week High | $116.66 | $73.82 |
52-Week Low | $85.25 | $40.32 |
Typical Hold Time | 68 Days | 0 Days |
Enterprise Value | — | $9.26B |
Signals from Pluang's Aura AI — not financial advice
ESPO trades at $100.43, up 0.08% today, with a bullish technical signal driven by strong moving average alignment. Key support lies at $97 and resistance at $98–$99. Financial ratios like P/E and P/S are unavailable in current data, limiting fundamental clarity. Recent news coverage is sparse, leaving sentiment largely neutral.
The stock's near-term outlook hinges on upcoming earnings to validate its technical strength. Risks include limited fundamental visibility and market volatility. Institutional positioning data is needed to gauge Wall Street confidence. Upside potential exists if resistance breaks, but caution is warranted without fresh catalysts.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
ESPO is a thematic ETF that invests in the global video gaming and eSports industry. It provides exposure to companies involved in game development, hardware, and streaming, including major firms like Tencent, Nintendo, and Electronic Arts.
Read more on ESPO →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →